Smartest Doc
A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy
Cancer Chemotherapy and Pharmacology, 08/16/2012
Clinical Article
Kim YH et al. – Ixabepilone is active in Asian patients with advanced gastric cancer and shows a toxicity profile similar to those previously reported in other tumor types.
Methods- Asian patients with unresectable or metastatic gastric adenocarcinoma who had failed fluoropyrimidine-based chemotherapy received ixabepilone 40 mg/m2 by 3-h intravenous infusion every 3 weeks.
- The primary endpoint was objective response rate (ORR).
- Fifty-two patients were treated (65.4 % men; median age: 56.5 years).
- The ORR was 15.4 % (95 % confidence interval [CI] 6.9-28.1); 8 patients achieved partial responses for a median duration of 3.1 months (95 % CI 2.6-4.1 months) and 26 patients (50.0 %) had stable disease.
- Median progression-free survival was 2.8 months (95 % CI 2.1-3.5 months).
- The most common grade 3 non-hematological toxicities were fatigue (9.6 %), decreased appetite (7.7 %), sensory neuropathy (5.8 %), and diarrhea (5.8 %).
- Grade 3/4 neutropenia occurred in 46.2 % of patients.
